ClinicalTrials.gg
Active, not recruitingNCT07311850VESPER-4Updated Oct 13, 2026

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

A Phase 3 interventional study of MET097 and Placebo in Obesity and Overweight, sponsored by Pfizer. Active, not recruiting at 161 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Updated Oct 13, 20266 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,578
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.

Enrollment
Largest of 21
3,578 · median 258
Started
2025
with 3 others
Phase 3
12 of 21
10 open now
Primary completion
2027-09
later than 3 of 14 live
Registered
6th of 21
by date
Lead sponsor
20 of 21
Pfizer

Among the 21 studies testing berobenatide in Obesity, this one has the largest enrollment, is one of 4 that started in 2025, is one of 12 in phase 3, reaches primary completion later than 3 of the 14 other live ones, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About berobenatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing berobenatide in Obesity, or all of them as a file.
02

Study summary

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

03

Conditions studied

  • Obesity and Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to \<30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Exclusion criteria

Exclusion Criteria:

  • Have any form of diabetes
  • Have a self-reported body weight change > 5 kg (11 pounds) within 3 months prior to Screening
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,578 participants (actual)

Study arms

  • Experimental
    MET097 Dose 1

    Participants will receive MET097 administered subcutaneously

    Drug: MET097

  • Experimental
    MET097 Dose 2

    Participants will receive MET097 administered subcutaneously

    Drug: MET097

  • Experimental
    MET097 Dose 3

    Participants will receive MET097 administered subcutaneously

    Drug: MET097

  • Placebo comparator
    Placebo

    Once-weekly placebo administered via subcutaneous injection

    Drug: Placebo

Interventions

  • DrugMET097

    Once-weekly MET097 administered via subcutaneous injection

    Also known as: PF-08653944

  • DrugPlacebo

    Once-weekly placebo administered via subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in body weight

    Time frame: Baseline (Day 0) to Week 64

Secondary outcomes

  1. Percentage of Participants who achieve ≥5% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 64

  2. Percentage of Participants who achieve ≥10% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 64

  3. Percentage of Participants who achieve ≥15% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 64

  4. Percentage of Participants who achieve ≥20% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 64

  5. Change from baseline in Fasting triglycerides

    Time frame: Baseline (Day 0) to Week 64

  6. Change from baseline in non-high-density lipoprotein-cholesterol (non-HDL-C) (mg/dL)

    Time frame: Baseline (Day 0) to Week 64

  7. Change from baseline in systolic blood pressure

    Time frame: Baseline (Day 0) to Week 64

  8. Change from baseline in the Short Form 36 health survey (SF-36) physical function domain score

    Time frame: Baseline (Day 0) to Week 64

  9. Change from baseline in body weight

    Time frame: Baseline (Day 0) to Week 84

  10. Percentage of Participants who achieve ≥5% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 84

  11. Percentage of Participants who achieve ≥10% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 84

  12. Percentage of Participants who achieve ≥15% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 84

  13. Percentage of Participants who achieve ≥20% of reduction from baseline body weight

    Time frame: Baseline (Day 0) to Week 84

  14. Change from baseline in Fasting triglycerides

    Time frame: Baseline (Day 0) to Week 84

  15. Change from baseline in non-high-density lipoprotein-cholesterol (non-HDL-C)

    Time frame: Baseline (Day 0) to Week 84

  16. Change from baseline in systolic blood pressure (mmHg)

    Time frame: Baseline (Day 0) to Week 84

  17. Change from baseline in the Short Form 36 health survey (SF-36) physical function domain score

    Time frame: Baseline (Day 0) to Week 84

  18. Change from baseline in waist circumference (cm)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  19. Change from baseline in glycated hemoglobin (HbA1c)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  20. Change from baseline in fasting plasma glucose (FPG)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  21. Change from baseline in fasting insulin

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  22. Change from baseline in total cholesterol

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  23. Change from baseline in low-density lipoprotein-cholesterol (LDL-C)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  24. Change from baseline in very low-density lipoprotein-cholesterol (VLDL-C)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  25. Change from baseline in high-density lipoprotein-cholesterol (HDL-C)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  26. Change from baseline in DBP

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  27. Percent change from baseline in high-sensitivity C-reactive protein (hs-CRP)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  28. Change from baseline in EuroQoL 5-Dimension 5-Level (EQ5D-5L)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  29. Change from baseline in Control of Eating Questionnaire (CoEQ)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  30. Change from baseline in Food Noise Questionnaire (FNQ)

    Time frame: Baseline (Day 0) to Week 64 and Week 84

  31. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Week 84

  32. Number of Participants with Serious adverse events (SAEs)

    Time frame: Week 84

  33. Number of Participants with Adverse Events of Clinical Interest (AECIs

    Time frame: Week 84

  34. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Week 84

  35. Number of participants with anti-drug antibodies (ADAs)

    Time frame: Week 84

  36. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08653944

    Time frame: Week 84

  37. Change from baseline in body weight

    Time frame: Baseline (Day 0) to Week 64

  38. Percent change from baseline in body weight

    Time frame: Baseline (Day 0) to Week 84

07

Study locations

161 sites

Showing the first 100 of 161 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 21 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Dec 31, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Sep 21, 2027
CompletionEst.
Apr 25, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites removed
Show 6 removed
  • Zentrum für klinische Forschung · Cologne, Germany
  • Centrum Terapii Współczesnej J.M. Jasnorzewska Spółka Komandytowo-Akcyjna · Lodz, Poland
  • Praktyka Lekarska Ewa Krzyzagorska · Poznan, Poland
  • Bodyline Medical Clinic, Crosby Civia Health · Liverpool, United Kingdom
  • Clifton Medical Centre · Rotherham, United Kingdom
  • Bodyline Medical Clinic, St Helens Civia Health · St Helens, United Kingdom
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    6 sites removed
    Show 6 removed
    • Zentrum für klinische Forschung · Cologne, Germany
    • Centrum Terapii Współczesnej J.M. Jasnorzewska Spółka Komandytowo-Akcyjna · Lodz, Poland
    • Praktyka Lekarska Ewa Krzyzagorska · Poznan, Poland
    • Bodyline Medical Clinic, Crosby Civia Health · Liverpool, United Kingdom
    • Clifton Medical Centre · Rotherham, United Kingdom
    • Bodyline Medical Clinic, St Helens Civia Health · St Helens, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07311850
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Dec 19, 2025
Primary completion
Sep 21, 2027 (estimated)
Completion
Apr 25, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion